MD edge: PRESERVED-HF: Dapagliflozin improves physical limitations in patients with HFpEF

September 14, 2021

The SGLT2 inhibitor dapagliflozin scored a clear win in a randomized, controlled trial with more than 300 U.S. patients with heart failure with preserved ejection fraction (HFpEF), showing a significant and clinically meaningful benefit for the primary endpoint, a KCCQ measure of symptoms and physical limitations, after 12 weeks of treatment.

In the PRESERVED-HF study, patients with HFpEF who received a standard, once-daily dose of dapagliflozin (Farxiga) had an average 5.8-point improvement in their condition as measured by the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CS), the study’s primary endpoint.

Read the full MD edge article: PRESERVED-HF: Dapagliflozin improves physical limitations in patients with HFpEF

Related Content

Saint Luke's Mid America Heart Institute
PRESERVED-HF trial findings on the substantial impact of dapagliflozin in individuals with heart failure with preserved ejection fraction (HFpEF) published in Nature Medicine
The findings of the PRESERVED-HF trial, offering potential new hope for people struggling with heart failure with preserved ejection fraction (HFpEF), are published in the journal, Nature Medicine.
<none>
Medpage Today: SGLT2 Inhibitor Eases Symptoms for HFpEF Patients
Symptoms of heart failure with preserved ejection fraction (HFpEF) improved with dapagliflozin (Farxiga) therapy, the PRESERVED-HF trial showed.
<none>
KMBC: Saint Luke's Mid America Heart Institute performs its 900th heart transplant
KMBC talked to Dr. Andrew Kao about the significance of the big milestone and lucky number 900 to learn his touching story.